Cover Image
市場調查報告書

非酒精性脂肪肝病(NAFLD): 開發平台分析

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 251566
出版日期 內容資訊 英文 176 Pages
訂單完成後即時交付
價格
Back to Top
非酒精性脂肪肝病(NAFLD): 開發平台分析 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 176 Pages
簡介

非酒精性脂肪肝病,是慢性肝疾病的最常見的原因之一。這個疾病,是常見的病,大部分的人雖沒看到症侯和併發症,不過,依不同人由於積蓄了脂肪的原因,肝臟會引起發炎和受傷。最顯著的症狀,有倦怠感、疲勞感、腹部右上四分之一或者全體擴散的不舒服。

本報告提供非酒精性脂肪肝病(NAFLD)的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的新聞和發表,也夾雜正在開發的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等。

非酒精性脂肪肝病(NAFLD) 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

各企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

在企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Arisaph Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Betagenon AB
  • Can-Fite BioPharma Ltd.
  • Conatus Pharmaceuticals Inc.
  • Corcept Therapeutics Incorporated
  • Daewoong Pharmaceutical Co., Ltd.
  • Dimerix Bioscience Pty Ltd
  • Dr. Falk Pharma GmbH
  • DURECT Corporation
  • Galmed Pharmaceuticals Ltd.
  • Gilead Sciences, Inc.
  • Huons Co., Ltd.
  • Kyorin製藥
  • Novartis AG
  • Sancilio & Company, Inc.
  • TaiwanJ Pharmaceuticals Co., Ltd.
  • TCM Biotech International Corp
  • Tobira Therapeutics, Inc.
  • Verva Pharmaceuticals Limited
  • Zafgen Inc.
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (白氨酸 + 鹽酸Metformin + 檸檬酸Sildenafil)
  • (白氨酸 + PDE5 抑制劑)
  • Aramchol
  • ARI-3037MO
  • C-10
  • cenicriviroc mesylate
  • CF-102
  • CORT-118335
  • DMX-300
  • 消化器官疾病、代謝障礙治療用 ABHD6抑制劑
  • DUR-928
  • DWP-10292
  • emricasan
  • FLB-12
  • GS-9674
  • HU-002
  • KDT-501
  • MAT-8800
  • methazolamide
  • MN-002
  • 鹽酸Naltrexone
  • norursodeoxycholic acid
  • O-304
  • oltipraz
  • pradigastat sodium
  • Px-103
  • saroglitazar
  • SC-410
  • 非酒精性脂肪性肝炎、非酒精性脂肪肝病治療藥
  • 脂肪肝病治療用AMPK活性藥
  • 代謝障礙治療用 NaCT抑制劑
  • TCM-606F
  • VVP-100-X
  • ZGN-839

最近的開發平台趨勢

暫停中的計劃

)■開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8972IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 15, 8, 2, 16 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Overview
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Arisaph Pharmaceuticals Inc
    • AstraZeneca Plc
    • Betagenon AB
    • Bird Rock Bio Inc
    • Can-Fite BioPharma Ltd
    • Cerenis Therapeutics Holding SA
    • Conatus Pharmaceuticals Inc
    • Corcept Therapeutics Inc
    • CymaBay Therapeutics Inc
    • Daewoong Pharmaceutical Co Ltd
    • Dimerix Bioscience Pty Ltd
    • Dr. Falk Pharma GmbH
    • DURECT Corp
    • Enanta Pharmaceuticals Inc
    • Eternygen GmbH
    • Galmed Pharmaceuticals Ltd
    • Gemphire Therapeutics Inc
    • Genfit SA
    • Gilead Sciences Inc
    • Huons Co Ltd
    • Immuron Ltd
    • Kyorin Pharmaceutical Co Ltd
    • Matinas BioPharma Holdings Inc
    • Miyarisan Pharmaceutical Company Ltd
    • NovaTarg Therapeutics Inc
    • Pfizer Inc
    • Renova Therapeutics Inc
    • Sancilio & Company Inc
    • TaiwanJ Pharmaceuticals Co Ltd
    • TCM Biotech International Corp
    • Zydus Cadila Healthcare Ltd
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles
    • (leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile
    • (leucine + PDE5 Inhibitor) - Drug Profile
    • AC-261066 - Drug Profile
    • Aramchol - Drug Profile
    • ARI-3037MO - Drug Profile
    • AZD-4076 - Drug Profile
    • C-10 - Drug Profile
    • CBM-588 - Drug Profile
    • cenicriviroc mesylate - Drug Profile
    • CER-209 - Drug Profile
    • CORT-118335 - Drug Profile
    • dapagliflozin propanediol - Drug Profile
    • DMX-300 - Drug Profile
    • Drug to Antagonize MCJ for Gastrointestinal Disorders - Drug Profile
    • DUR-928 - Drug Profile
    • DWP-10292 - Drug Profile
    • EDP-305 - Drug Profile
    • elafibranor - Drug Profile
    • emricasan - Drug Profile
    • FLB-12 - Drug Profile
    • gemcabene calcium - Drug Profile
    • GS-0976 - Drug Profile
    • GS-9674 - Drug Profile
    • HTD-1801 - Drug Profile
    • HU-002 - Drug Profile
    • IMM-124E - Drug Profile
    • liothyronine sodium - Drug Profile
    • MAT-8800 - Drug Profile
    • MN-002 - Drug Profile
    • naltrexone hydrochloride - Drug Profile
    • Namacizumab - Drug Profile
    • namodenoson - Drug Profile
    • NLM-0100 - Drug Profile
    • norursodeoxycholic acid - Drug Profile
    • O-304 - Drug Profile
    • oltipraz - Drug Profile
    • PF-06835919 - Drug Profile
    • RT-200 - Drug Profile
    • RT-210 - Drug Profile
    • saroglitazar - Drug Profile
    • SC-410 - Drug Profile
    • seladelpar - Drug Profile
    • selonsertib - Drug Profile
    • Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile
    • Small Molecules for Non-Alcoholic Steatohepatitis and Non Alcoholic Fatty Liver Disease - Drug Profile
    • Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile
    • Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile
    • Synthetic Peptides for Non Alcoholic Fatty Liver Disease and Non Alcoholic Steatohepatitis - Drug Profile
    • TCM-606F - Drug Profile
    • tipelukast - Drug Profile
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Allergan Plc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bird Rock Bio Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CymaBay Therapeutics Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corp, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Enanta Pharmaceuticals Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gemphire Therapeutics Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Genfit SA, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Immuron Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovaTarg Therapeutics Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Pfizer Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Renova Therapeutics Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio & Company Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top